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Abstract
Background: Mammalian cells synthesize morphine and the respective biosynthetic pathway has been elucidated. Human
neutrophils release this alkaloid into the media after exposure to morphine precursors. However, the exact role of
endogenous morphine in inflammatory processes remains unclear. We postulate that morphine is released during infection
and can be determined in the serum of patients with severe infection such as sepsis.
Methodology: The presence and subcellular immunolocalization of endogenous morphine was investigated by ELISA, mass
spectrometry analysis and laser confocal microscopy. Neutrophils were activated with Interleukin-8 (IL-8) or
lipopolysaccharide (LPS). Morphine secretion was determined by a morphine-specific ELISA. m opioid receptor expression
was assessed with flow cytometry. Serum morphine concentrations of septic patients were determined with a morphine-
specific ELISA and morphine identity was confirmed in human neutrophils and serum of septic patients by mass
spectrometry analysis. The effects of the concentration of morphine found in serum of septic patients on LPS-induced
release of IL-8 by human neutrophils were tested.
Principal Findings: We confirmed the presence of morphine in human neutrophil extracts and showed its colocalisation
with lactoferrin within the secondary granules of neutrophils. Morphine secretion was quantified in the supernatant of
activated human polymorphonuclear neutrophils in the presence and absence of Ca
2+. LPS and IL-8 were able to induce a
significant release of morphine only in presence of Ca
2+. LPS treatment increased m opioid receptor expression on
neutrophils. Low concentration of morphine (8 nM) significantly inhibited the release of IL-8 from neutrophils when
coincubated with LPS. This effect was reversed by naloxone. Patients with sepsis, severe sepsis and septic shock had
significant higher circulating morphine levels compared to patients with systemic inflammatory response syndrome and
healthy controls. Mass spectrometry analysis showed that endogenous morphine from serum of patient with sepsis was
identical to poppy-derived morphine.
Conclusions: Our results indicate that morphine concentrations are increased significantly in the serum of patients with
systemic infection and that morphine is, at least in part, secreted from neutrophils during sepsis. Morphine concentrations
equivalent to those found in the serum of septic patients significantly inhibited LPS-induced IL-8 secretion in neutrophils.
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Introduction
Morphine was first identified in opium from Papaver somniferum,
and is one of the strongest known analgesic compounds [1].
Endogenous morphine has been characterized in several mam-
malian cells and tissues [2,3,4]. In mammals, the biosynthesis of
endogenous morphine is associated with dopamine [5,6,7], as
demonstrated in the SH-SY5Y human neuronal catecholamine-
PLoS ONE | www.plosone.org 1 January 2010 | Volume 5 | Issue 1 | e8791producing cell line [8,9]. More recently, we showed that m opioid
receptors as well as their ligands morphine and morphine-6-
glucuronide (M6G) are present in the human neuroblastoma SH-
SY5Y cell line and that morphine is secreted from the large dense
core vesicles in response to nicotine stimulation via aC a
2+-
dependent mechanism [10].
Endogenous morphine or precursors were also found in
peripheral organs including adrenal gland [3,11] and liver
[12,13]. In addition, our group reported the presence of
morphine-6-glucuronide (M6G) bound to phosphatidylethanol-
amine-binding protein/RKIP [14], in the secretory granules and
secreted material of bovine adrenal chromaffin cells [14,15].
Secretion of endogenous alkaloids together with catecholamines
into the blood is likely to occur during stress situations and could
be involved in different stress- or pain-modulating mechanisms via
binding to m opioid receptors expressed on numerous cell types
including endothelial and immune cells [16,17,18].
Recently, new insights were gained from studies showing the
production of morphine by human polymorphonuclear cells
(PMN) [19]. However, the presence of morphine in neutrophils
as well as the occurrence of morphine in serum is matter of debate,
in particular, since morphine production could be attributed to
either erythrocytes [20] or neutrophils. Human neutrophils were
shown to be able to release morphine into the media after
exposure to precursors including L-tyrosine, L-DOPA, tetrahy-
dropapaveroline (THP) and reticuline. Stimuli such as alcohol,
nicotine, and cocaine induce morphine release from human white
blood cells in vitro [21]. Furthermore, a nonclassical cholinergic
regulation of morphine release from human white blood cells was
demonstrated [22]. Leukocytes play an important role in innate
immune responses and represent a major defense mechanism
against infection. During sepsis, PMN are also involved in organ
dysfunction, such as acute lung injury or acute kidney failure [23].
However, the role of endogenous morphine in inflammation
remains unclear, and knowledge of its secretion from immunocytes
as well as its subcellular localization is lacking. Several studies
suggest a role of endogenous morphine in maintaining homeostasis
as part of the response to stress, in particular inflammation or
infection. Interestingly, a recent paper reported that low
concentrations of morphine (10–100 nM) enhanced migration of
primary microglial cells toward adenosine diphosphate via a m
opioid receptor-dependant mechanism [24].
Endogenous morphine levels have been investigated after
surgical intervention and have been found to be elevated after
cardiovascular bypass [25,26]. Morphine concentrations in the
blood are higher after open cholecystectomy compared with
laparoscopic cholecystectomy as the less invasive surgical proce-
dure [27]. In addition, LPS administration to rats dramatically
increased the amount of circulating and cerebral endogenous
morphine [28,29]. An increase of morphine in blood was also
observed upon fasting conditions [12].
The present study focuses on the presence of endogenous
morphine in the serum of patients with sepsis. First, we have
shown the presence of morphine in secondary granules containing
lactoferrin and characterized the secretion of morphine as well as
expression of the m opioid receptor in LPS- and IL-8 stimulated
human neutrophils from healthy donors. Effects of low concen-
tration of morphine on LPS-induced IL-8 secretion from human
neutrophils were also studied. Secondly, we determined morphine
levels in the serum of septic patients. Together, our data suggest
that in patients with systemic inflammation and infection
morphine secretion into the blood is part of their immune
response and might represent a biological marker of these
conditions.
Materials and Methods
Isolation of Human PMN
Human PMN were prepared from buffy coats obtained from
EFS (Etablissement Franc ¸ais du Sang, Strasbourg, France) by
centrifugation as previously described [30]. Briefly, 50 ml of buffy
coat were diluted (2:3, v:v) in sodium chloride buffer (0.9%, w:v). A
30 ml suspension was gently loaded on 12 ml of lymphocyte
separation medium (Eurobio, France). After centrifugation (800 g,
20 min), pellets containing PMN were washed with NaCl 0.9%.
PMN were suspended in 30 ml NaCl 0.9% and 10 ml Dextran
6% (U.S.B., USA), and mixed vigorously. After 1 hour of
sedimentation, the supernatant was recovered and centrifuged
(800 g, 15 min). Pellets were washed in NaCl 0.9% and
resuspended in erythrocyte lysis buffer (Qiagen, France), kept
5 min on ice before addition of NaCl 0.9%, then centrifuged
(800 g, 15 min). Pellets of PMN were finally suspended in 10 ml
RPMI 1640 (Sigma-Aldrich, France). The cell population
obtained with this technique contains more than 95% neutrophils
[31]. Cell viability and cell yield were evaluated by Trypan blue
exclusion, using a Neubauer chamber and an optic microscope.
For none of the in vitro experiments a significant increase in cell
death compared to controls was observed.
Immunohistochemistry
In order to observe the presence of morphine immunoreactivity
in both neutrophils and erythrocytes, a drop of fresh healthy
human blood was spread on a glass slide and let dry for 3 min at
RT. Blood cells were fixed with 5 soaking of 1 sec in 100%
methanol at RT. Cells were permeabilized with a solution of PFA
2% in acetone (v:v) during 2 min at 220uC. After drying the
immunodectection was carried on as described below.
Cytospins were prepared by centrifugation of 2.5.10
5 isolated
PMNs onto glass slides (800 g, 10 min). Cells were fixed 20 min
with 4% paraformaldehyde (w:v, Sigma Aldrich, France) in
phosphate-buffered saline (PBS, 0.9% NaCl and 25 mM sodium
phosphate, pH 7.4; Euromedex, France). Cells were permeabi-
lized for 1 min with 0.05% (v:v) Triton X100 in PBS [15].
Immunostaining was performed as previously described [32].
Slides were washed in PBS and incubated for 1 h in horse serum
diluted in PBS (10%, v:v) in order to saturate nonspecific
immunoreactive sites. After six PBS washes (5 min), coverslips
were incubated overnight in different antisera. Primary antibodies
were used as follows: (i) mouse monoclonal 6D6 (Aviva System
Biology, USA; dilution 1:2000) raised against morphine-like
compounds (morphine, morphine-3-glucuronide, and M6G, based
on supplier specifications and our own experiments) and (ii) rabbit
anti-lactoferrin polyclonal antibody (dilution 1:5000) [33].
After incubation with the primary antibody, slides were washed
six times with PBS (5 min) and specific secondary antisera were
added for 2 h at room temperature, followed by six PBS washes
(5 min). These secondary antisera were (i) Cy5-conjugated donkey
anti-mouse IgG (Jackson Immunoresearch Laboratories, USA,
dilution 1:2,000) and (ii) Cy3-conjugated donkey anti-rabbit IgG
(Jackson Immunoresearch Laboratories; dilution 1:2000).
Several controls were carried out to assess antibody specificity
and nonspecific immunoreactivity. Primary antibodies were
omitted, and each secondary antibody was tested individually or
in a mixture in the presence of cells. Control for morphine antibody
was carried out by incubating the antibody with morphine (2 h,
25uC, 50:1, w/w), prior to immunocytochemistry experiments.
Each antibody was also tested with the secondary antibody used
for the second immunolabelling in order to determine whether
interspeciescross-reactivityexists.Anti-morphine 6D6antibodywas
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morphine, M6G, and morphine-3-glucuronide (M3G), showing a
specificity for morphine, M6G, M3G, and codeine (Fig. 1A). No
cross reactivity was found for adrenaline, noradrenaline, dopamine
and tetrahydropapaveroline (Sigma-Aldrich, France).
Confocal Microscopy
Immunofluorescent staining was analyzed with a Leica laser
scanning microscope (TCS-SP2 invert) equipped with a plan apo
63X oil immersion lens. Tissue sections were subjected to optical
serial sectioning to produce images in the X–Y plane. Each optical
section was scanned eight times for brain sections and four times
for cells to obtain an average image. Pictures were recorded
digitally in a 5126512 pixel format. A look-up table (glowover-
glowunder, Leica) ensured that the full dynamic range of the
photomultipliers was used. Before each measurement, a series of
sections was acquired through the vertical axis in order to choose
the equatorial section.
Stimulation of PMN with LPS
Immediately after isolation, 20.10
6 neutrophils in 200 mlo f
EGTA buffer (140 mM NaCl, 5 mM KCl, 10 mM glucose,
0.1 mM EGTA, 10 mM Hepes, 3 mM Tris; pH 7.3) with or
without 1.1 mM CaCl2, were preincubated in low binding tubes
for 30 min (37uC, 5% CO2) prior to stimulation. To stimulate
PMN, LPS (E. coli, O111:B4; 10 ng/ml in 200 ml reaction volume,
Sigma-Aldrich) was added to the medium and cells were incubated
for 6 h at 37uC, 5% CO2 [34]. After incubation, supernatants
were recovered by centrifugation (800 g, 10 min), and 40 ml was
tested (in duplicate) for the presence of morphine using a
morphine-specific ELISA kit (see below). In controls, LPS was
replaced by EGTA buffer with and without Ca
2+ Additional
control experiments with LPS alone (without cells) revealed an
absence of cross-reactivity with the ELISA. Secretion efficiency
was checked by Western blot analysis (see below) using an
antibody against a secretion marker (i.e., lactoferrin).
Stimulation of Neutrophils with IL-8
Neutrophils (20.10
6 cells) were preincubated in 200 ml EGTA
buffer with or without 1.1 mM CaCl2 for 30 min at 37uC prior to
stimulation. Neutrophils were stimulated in 200 ml reaction
volumes, as previously described [34,35]. Cells were incubated
with cytochalasin B (5 mg/ml, 5 min, Sigma-Aldrich) prior to IL-8
stimulation (50 nM, 7 min; R&D Systems Europe, France). After
centrifugation (800 g, 10 min), supernatants were recovered and
analyzed using a morphine-specific ELISA kit (see below). In
controls, IL-8 was replaced by EGTA buffer with and without
Ca
2+. Additional control experiments with IL-8 and cytochalasin B
alone (without cells) revealed an absence of cross-reactivity with
the ELISA. Secretion efficiency was checked by Western blot
analysis (see below) using an antibody against a secretion marker
(i.e., lactoferrin).
Alkaloid Analysis
10 ml of serum from septic patients (n=3), as well as serum
from healthy donors (n=3), human neutrophils (140 to 200.10
6
cells) and alkaloid standards, were deproteinized as previously
described [36]. Deproteinized sample extracts were dissolved in
0.1% trifluoroacetic acid in H2O (v:v) prior to solid phase
extraction. Samples were loaded on a Sep Pack cartridge (Waters
Corporation) previously activated with 10 ml of 100% acetonitrile
and washed with a solution of 0.1% trifluoroacetic acid in H2O
(v:v). Elution was performed with a solution of 15% acetonitrile
with 0.1% trifluoroacetic acid in H2O (v:v:v). Eluted samples were
dried with a SpeedVac evaporator. In order to determine the
recovery of morphine present in the serum samples, 4 different
amounts of exogenous morphine were added to 1 ml of morphine-
free serum (0.5, 1, 5 and 10 ng/ml, n=3). The percentage of
recovery calculated for the extraction steps before the mass
spectrometry (MS) analysis was 62.7+/211%.
Mass Spectrometry
Mass spectrometry (MS) and MS-MS analyses were performed
using electrospray mass spectrometry on a Q-TOF II (quadrupole-
time of flight, Bio-Tech) in positive mode as previously described
[10,15].
Gel Electrophoresis and Western Blot Analysis
Proteins were separated on SDS-PAGE gradient gels (4%–12%
acrylamide; Criterion XT, BioRad) and electrotransferred onto
polyvinyldifluorene membranes (GE Healthcare Bioscience, Swe-
den) [37]. SH-SY5Y cell extract was used as a positive control.
Human lactoferrin (75 kDa) was detected using a rabbit poly-
clonal antibody (dilution 1:5,000 [33]) and revealed using HRP-
conjugated anti-rabbit antisera (Sigma Aldrich, dilution 1:400,000)
and Supersignal West Femto Kit (Pierce, USA). For m opioid
receptor detection, 50 mg of neutrophil extract was loaded on the
gel. The m opioid receptor was detected using a goat anti-MOR1
antibody (N-20; Santa Cruz Biotechnology, USA; dilution 1:3,000)
and revealed using HRP-conjugated anti-goat antisera (Jackson
immunoresearch, England; dilution 1:50,000). Control experi-
ments omitting the primary antibody confirmed the specificity of
the label. Apparent molecular weights were evaluated by
comparison with molecular weight standards (Bio-Rad).
Morphine-Specific ELISA
A morphine-specific ELISA kit (Immunalysis Corporation,
USA) was used for determination of morphine present in culture
medium (40 ml in duplicate; n=6 or 7) or in the serum of patients
(20 ml, in duplicates). The specificity of the test for morphine was
confirmed by testing different amounts of dopamine, adrenaline,
noradrenaline, M6G, M3G, and codeine (0–25 ng/ml, data not
shown). For all tests, morphine standards were diluted in the
appropriate buffer. The CV values were between 0% to 8%. All
samples with a higher CV value were retested in order to obtain a
CV below or equal to 8%. The calculated methodological
detection limit of the batch of ELISA kit use for the study was
0.01 ng/ml of morphine. No cross reactivity for LPS, IL-8, or
cytochalasin B was found (i.e., the values of morphine were under
the detection limit). The linearity of morphine detection in
morphine-free serum is illustrated in Fig. 2A.
IL-8 Secretion Assay and Quantification
Neutrophils were treated as previously described [38]. Briefly,
neutrophils (1.10
6 cells/well) were cultured in 24-well plates in
1 ml of complete RPMI 1640 nutrient (Sigma Aldrich) supple-
mented with 10 mM HEPES (Sigma Aldrich), 2 mM L-glutamine
(Sigma Aldrich), 100 U/ml penicillin, 100 mg/ml streptomycin,
0.25 mg/ml amphotericin B, and10% fetal bovine serum in a
moist atmosphere containing 5% CO2 at 37uC for 24 h in the
presence of 10 ng/ml LPS, 8nM morphine (i.e., 2.25ng/ml) and/
or 10 mM naloxone. LPS and morphine were added to cultures
simultaneously, whereas the naloxone was added 30 min before
treatments. Supernatants from cell cultures were collected,
centrifuged for 10 min at 800 g, and stored in the frozen state
at 220uC.
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PLoS ONE | www.plosone.org 3 January 2010 | Volume 5 | Issue 1 | e8791Figure 1. Evidence of the presence of morphine-like immunoreactivity in human neutrophils. A. ELISA showing the specificity of the 6D6
antibody. B. Upper panel, double immunofluorescence confocal micrographs performed on purified neutrophils from healthy donors. Labeling was
performed with a mouse anti-morphine antibody (visualized in green pseudocolor with a Cy5-conjugated IgG) and with an antibody against
lactoferrin (a secondary granule marker) visualized in red pseudocolor with a Cy3-conjugated IgG. Colocalized immunolabelling (merged window)
appears as yellow staining. Lower panel, higher magnification. C. Immunofluorescence confocal micrographs performed on a blood drop from an
healthy donor. Labeling was performed with a mouse anti-morphine antibody (visualized in green pseudocolor with a Cy5-conjugated IgG). Phase
contrast allows to observe both neutrophils and erythrocytes. Merged window correspond to the supperposition of the two pictures. D. To assess the
specificity of the secondary antibody, control experiments were performed using Cy3-conjugated IgG or Cy5-conjugated IgG without primary
antibody. Controls for morphine immunoreactivity were carried out by preincubating the antibody with morphine.
doi:10.1371/journal.pone.0008791.g001
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was assayed with a commercial human IL-8 ELISA (BD
Biosciences, USA) according to manufacturer instructions. ELISA
sensitivity for IL-8 was 0.8 pg/ml with a working range being
between 0.8 to 200 pg/ml. If required, samples were diluted with
the bufferused for the stimulationassay. The ELISA was performed
on 100 ml of samples in duplicates. The CV values were between
0% and 8%. All samples with a higher CV value were retested in
order to obtain a CV below or equal to 8%. No cross-reactivity for
LPS, morphine or naloxone was found (data not shown).
Validation of the 6D6 Antibody by ELISA
Morphine 6D6 antibody specificity was tested on a 96 wells
plate (NUNC, Roskilde, Denmark) coated overnight at room
temperature with 200 mL of a 100 ng/ml morphine-BSA solution
(Fitzgerald Industries International, USA). After three washes with
PBS-0,05% tween buffer, wells were incubated for 1 hour with
200 ml of BSA diluted in PBS buffer (5%, w/v) in order to saturate
nonspecific sites. After saturation wells were incubated 30 min
with 100 ml of PBS-BSA (3%, w/v) containing 0 ng/ml,
0.02 ng/ml, 0.2 ng/ml, 2 ng/ml, 20 ng/ml, 200 ng/ml and
2 mg/ml of the following potential antigens: morphine (Sigma-
Aldrich), M6G (Sigma-Aldrich), M3G (Sigma-Aldrich), codeine
(Sigma-Aldrich) and dopamine (Sigma-Aldrich). 100 ml of the
mouse monoclonal primary antibody (6D6, Aviva System Biology;
dilution 1:2000) in PBS-BSA (3%, w/v) were added in each wells.
After 3 hours incubation at RT, the plate was washed three times
with PT buffer and 200 ml of the secondary antibody (HRP-
conjugated donkey anti-mouse IgG, P.A.R.I.S.; dilution 1:400)
was added and let in the wells during 2 hours at RT. After two
washes with PBS-0,05% tween buffer followed with two washes
with a pH 7,5 phosphate-citrate-0,05% tween buffer (CT),
revelation was performed with 200 ml of a freshly solution of
ortho-penylene diamine (OPD; Sigma Aldrich) at 1,5 mg/ml in
CT buffer containing 0,075% hydrogen peroxide. After 20 min of
incubation at RT, optical density was determined at 450 nm on a
Multiskan EX plate reader (Thermo Life Sciences, France). The
50% displacement point of the antibody for an antigen is
determined with KyPlot 2.0 (after a sigmoidal fit of the results).
Flow Cytometric Determination of m Opioid Receptor
Expression on Neutrophils
m opioid receptor expression was determined as described
before [39]. Briefly, 100 ml blood was stimulated with LPS
(100 ng/ml) for 3, 6, 12 and 24 h (37uC in a 95% air/5% CO2
atmosphere). Incubation with NaCl 0.9% served as control.
Samples were spun down (10 min, 250 g) and incubated with
(FITC)-conjugated antibodies against the N-terminus (N-20; Santa
Cruz Biotechnology) or the the C-terminus (C-20; Santa Cruz
Biotechnology) of the m opioid receptor for 15 min. FITC-labeled
antibodies against human IgG were used to rule out unspecific
binding and for cytometer setup. All antibodies were purchased
with FITC tag (Camon-Serotech, Germany). Samples were spun
down after incubation with anti-MOR (10 min, 250 g). For red
cell lysis, FacsH Brand Lysing Solution (Becton Dickinson,
Germany) was added. After incubation for 10 minutes samples
were centrifuged (5 min, 250 g), washed twice with PBS and
analyzed by flow cytometry. Flow cytometric analysis was
performed using a FACSCaliburH (Becton Dickinson) flow
cytometer with argon ion laser excitation at 488 nm, with 15000
events of each sample measured. Data were acquired and
processed using CellQuestH software. Neutrophils were identified
and live gated by their special characteristics in forward angle light
scatter (FSC) and 90u side scatter (SSC). Medians of fluorescence
intensities (MFI) of antibody-stained granulocytes were determined
as a measure of m opioid receptor expression. Using histogram
analysis, the percentage of neutrophils which responded to
stimulation with a high m opioid receptor expression was
determined.
PCR and Gel Eletrophoresis
Neutrophils (5.10
6 cells/well) were cultured in 24-well plates in
1 ml of complete RPMI 1640 nutrient (Sigma Aldrich) supple-
mented with 10 mM HEPES (Sigma Aldrich), 2 mM L-glutamine
(Sigma Aldrich), 100 U/ml penicillin, 100 mg/ml streptomycin,
0.25 mg/ml amphotericin B, and10% fetal bovine serum in a
moist atmosphere containing 5% CO2 at 37uC for 24 h in the
presence of 100 ng/ml LPS. Total RNA was isolated using
Figure 2. Morphine secretion from human primary neutrophils.
A. Typical dose-response curve of the morphine detection performed
with the morphine-specific ELISA. B. Upper panel, Morphine secreted
from neutrophils expressed as pg/ml. Morphine was quantified in culture
medium after stimulating 20.10
6 neutrophils with LPS (10 ng/ml, 6 h;
n=6) in presence or absence of Ca
2+. Basal secretion levels were
obtained from neutrophils incubated without LPS (6 h; n=6). Lower
panel, Efficiency of secretion was assessed by monitoring the secretion of
lactoferrin (75 kDa, a marker of secondary granules) by Western blot
analysis. C. Upper panel, Morphine was quantified in culture medium
after stimulating 20.10
6 neutrophils with IL-8 (50 nM, 7 min; n=7) in
presence or absence of Ca
2+. Basal secretion levels were obtained from
neutrophils incubated without IL-8 (7 min; n=6). Lower panel, The
efficiency of secretion was assessed by monitoring the secretion of
lactoferrin (75 kDa, a marker of secondary granules) by Western blot
analysis (50 mg). Amounts of secreted morphine in the LPS and IL-8
groups were statistically different from the two control groups (no LPS
and IL-8; *: p,0.01 with a Mann-Whitney test after Bonferroni correction.
doi:10.1371/journal.pone.0008791.g002
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protocols. The cDNA synthesis reaction were performed with 1 mg
of total mRNA and 100 U of SuperScript II reverse transcriptase
(InVitroGen, Paris, France) with random hexamers in a final
volume of 20 mL according to the manufacturer’s protocols. The
quality of the total RNA was assessed by the intensity of 28S and
18S bands after denaturing agarose electrophoresis. The RNA
concentration was determined by UV spectrophotometry. One
round of cDNA synthesis was performed in a thermal cycler (65uC
for 5 minutes before adding RT mix, 42uC for 50 min, and 65uC
for 5 minutes).
PCR was performed according to the manufacturer’s protocol
(0.25 mmol/l of primers from SABiosciences; OPRM1, RefSeq
Accession NM_000914.2, band size: 85 bp) and 3 mmol/l of
MgCl2, 1 mL of DMSO 20%, 2 mL of PCR mix containing Taq
polymerase) in a 20 mL final volume with a thermocycler
(LightCycler, Roche, France). The HotStart Taq polymerase
(Roche Diagnostics, Meylan, France) was activated by heating for
8 min at 95uC. Duplicate PCRs were performed for 50 cycles with
20 s of denaturation at 95uC, 20 s of hybridisation at 60uC
followed by 20 s of elongation at 72uC for each cycle. The quality
of products was confirmed by gel electrophoresis to confirm
OPRM1amplification size (85 pb).
Determination of Morphine Levels in Critically Ill Patients
Ethics statement. This part of the study was approved by
our institutional review board for human experimentation (Study
nu3/98 of the 09/12/2003 from the ‘‘CPPRB d’Alsace nu1
Strasbourg’’). Written informed consent was obtained from each
participant or from an authorized representative before
enrollment. Patients admitted between July and September 2007
to our intensive care unit (ICU) were prospectively considered for
inclusion. Samples from healthy volunteers served as controls.
Patients that were given exogenous morphine or codeine before or
during admission were excluded. After centrifugation, serum was
collected in tubes without anticoagulant agents in order to prevent
interactions with endogenous alkaloids.
Patients (n=48) were divided into five groups according to
ASCCP/SCCM (American College of Chest Physicians/Society
of Critical Care Medicine [40]; Table 1) criteria: (i) healthy
donors, (ii) patients with Systemic Inflammatory Response
Syndrome (SIRS), (iii) patients with sepsis (S), (iv) patients with
severe sepsis (SS), and (v) patients with septic shock (SSH). Body
temperature, positive microbiological results, white cell count and
inflammatory markers (C-reactive protein, procalcitonin) were
documented.
Daily serum morphine analysis (20 ml) was performed during
the first 3 days after admission. Routine physiological and
biochemical variables were recorded and Simplified Acute
Physiological Scores (SAPS) were calculated according to
standards [40].
Statistical Analysis
R version 2.80 and MINITAB V15 (Minitab Inc., France) were
used for data analysis. P levels ,0.05 were considered significant.
Data failed to be normally distributed (Q-Q plots and Shapiro-
Wilk test), so that non-parametric analysis was performed as
described below.
Statistical analysis of neutrophil secretion experi-
ments. In order to assess morphine and IL-8 secretion after
stimulation with IL-8 or LPS, six or seven independent
experiments were performed. Mann-Whitney test was performed
to test for significant changes. For multiple comparisons, the
significance level was adjusted using Bonferroni correction.
Statistical analysis of m opioid receptor expression
experiments. Statistical analysis was performed using Fried-
man’s test followed by Wilcoxon-Wilcox procedure, allowing
multiple comparisons between groups.
Statistical analysis of morphine levels in critically ill
patients. Kruskal-Wallis test followed by Dunn’s procedure for
post-hoc analysis was performed for data which were not normally
distributed.
Results
Characterization of Endogenous Morphine Present in
Neutrophils
Four different batches of neutrophils were extracted (140 to
200.10
6 cells per extract) and purified. The fraction resulting from
the elution procedure was analyzed with a Q-TOF MS-MS
approach. Comparison with a morphine standard allowed the
unambiguous identification of morphine (m/z=285.9 Da) and its
degradation fragments in the 4 neutrophil extracts (data not
shown). No M3G, M6G was detected. The amount of the
morphine determined by ELISA and MS analysis was 0.32+/
20.2 pg/million of neutrophils 6 SD (n=4). This value is
lower than the value previously found (12.3365.64 pg/million
cells 6 SD) [19], however, we could confirm that morphine is
present in human neutrophils
Subcellular Localization of Morphine in Human
Neutrophils
First, the specificity of the antibody 6D6 was tested using a
competitive ELISA (Fig. 1A). It appears that the 6D6 antibody
displays a high affinity for M6G (50% displacement point=0.07 nM
or 0.038 ng/ml), but also reacts with morphine (18.82 nM or
3.91 ng/ml), M3G (13 nM or 4.98 ng/ml) and codeine (7.95 nM or
2.29 ng/ml). According to our MS-MS analysis, only morphine is
produced by neutrophils, indicating that the immunolabel found with
the 6D6 antibody only reflects presence of endogenous morphine.
Second, using laser confocal microcopy, the labeling obtained
with the anti-morphine mouse monoclonal antibody was com-
pared to that of lactoferrin, a specific marker of secondary granules
(or specific granules) present in neutrophils [41]. Morphine
immunolabeling showed a punctate pattern in the cytoplasm,
similar to that obtained with an anti-lactoferrin antibody (Fig. 1B,
upper panel). Well-defined restricted immunolabelings in specific
structures were observed using higher magnification (Fig. 1B,
lower panel). Superimposition of the two labelings revealed a
colocalization within lactoferrin-containing granules (i.e., second-
ary granules; Fig. 1B, yellow label).
Finally, the presence of morphine in erythrocytes which was
described in previous reports [20] was studied by immunocyto-
chemistry. Fresh blood drops were spread on a glass slice and
immunocytochemistry using the 6D6 antibody was performed.
Fig. 1C shows the presence of morphine-like immunoreactivity in
neutrophils, whereas no immunoractivity is present in erythrocytes.
Control experiments established the specificity of the labeling in
granules using either secondary antibodies alone or the mouse
anti-morphine antibody blocked with morphine prior to its use in
immunocytochemistry experiments (Fig. 1D).
In conclusion, this experiment revealed morphine immunore-
activity within the secondary granules of human neutrophils,
suggesting its potential secretion upon cell stimulation.
Morphine Secretion from Human PMN
The amount of morphine released into the medium by
neutrophils after LPS or IL-8 stimulation was detected with a
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PLoS ONE | www.plosone.org 7 January 2010 | Volume 5 | Issue 1 | e8791sensitive morphine-specific ELISA kit (Fig. 2A). Control experi-
ments using IL-8 and cytochalasin B or LPS in the absence of
neutrophils ruled out cross-reactivity of these substances with the
ELISA (data not shown). Figure 2B (upper panel) shows the
increase of morphine secretion in cultured human neutrophils
stimulated with LPS (158635 pg/10
6 neutrophils 6SD, n=6). A
low basal level of morphine secretion was observed in the absence
of LPS (10624 pg/10
6 neutrophils 6SD, n=6). Secretion
efficiency was checked by Western blot analysis (50 mg) using an
antibody against lactoferrin which is present in and secreted by
secondary granules [41]. Lactoferrin was detected in both non
stimulated and LPS stimulated samples. However, the amount of
lactoferrin was higher in the supernatant of LPS stimulated
neutrophils (Fig. 2B, lower panel). The presence of lactoferrin in
the supernatant of unstimulated neutrophils might be caused by
the basal secretion from neutrophils activated by their artificial
environment, however, the rate of cell death was not increased
compared to controls.
In order to observe whether morphine secretion is Ca
2+-
dependent, identical experiments were performed in the absence
of Ca
2+. Without Ca
2+ in the media, basal secretion remained
unchanged (9621 pg/10
6 neutrophils 6SD, n=6), while LPS-
induced secretion of morphine decreased significantly (69615 pg/
10
6 neutrophils 6SD, n=6, p,0.01).
In parallel, PMN were treated with 50 nM IL-8 for 7 min
(Fig. 2C, upper panel) to trigger direct secretion of secondary
granules [34,41]. In the presence of IL-8, morphine secretion was
attenuated, but still significant (6067 pg/10
6 neutrophils 6SD,
n=6) compared to baseline (1667 pg/10
6 neutrophils 6SD,
n=6). Western blot analysis confirmed the presence of lactoferrin
in IL-8 treated cell medium (Fig. 2C, lower panel) and its absence
in nonstimulated cell medium after 7 min. Without Ca
2+, the basal
secretion of morphine was not significantly changed compared to
controls with Ca
2+ (1466 pg/10
6 neutrophils 6SD, n=6),
however, IL-8-induced secretion of morphine decreased signifi-
cantly under Ca
2+-free conditions (1566 pg/10
6 neutrophils
6SD, n=6, p,0.01).
In conclusion, the present results demonstrate that human
neutrophils secrete morphine via aC a
2+-dependent mechanism in
response to LPS or IL-8 stimulation.
Effects of Morphine on IL-8 Secretion
Human neutrophils (1.10
6 cells) were stimulated with 10 ng LPS
and/or morphine (8 nM corresponding to 2.25 ng/ml) and/or
10 mM naloxone (MOR antagonist) to determine the impact of
low morphine concentrations on IL-8 secretion after 24 h (Fig. 3).
Using a commercial IL-8 ELISA, no significant differences were
found between controls without LPS (no stimulation, 1662 ng/
10
6 neutrophils 6SD, n=6), morphine (1363 ng/10
6 neutrophils
6SD, n=6, p.0.05) and naloxone alone (1461.4 ng/10
6
neutrophils 6SD, n=6, p.0.05). Compared to controls LPS
significantly increased the release of IL-8 (3263 ng/10
6 neutro-
phils 6SD, n=6, p,0,05). Costimulation of neutrophils with LPS
and morphine decreased the release of IL-8 significantly
(2462 ng/10
6 neutrophils 6SD, n=6, p,0,05). Coincubation
of neutrophils with LPS and naloxone increased the secretion of
IL-8 significantly (5366 ng/10
6 neutrophils 6SD, n=6, p,0,05)
compared to LPS-alone (Fig. 3), suggesting a negative feedback
mechanism of endogenous morphine secreted upon LPS stimula-
tion. Finally, naloxone was able to significantly inhibit the effect of
exogenous morphine on neutrophils treated with LPS compared to
LPS and morphine incubation alone (4965 ng/10
6 neutrophils
6SD, n=6, p,0,05).
In conclusion, our results indicate that low concentrations of
morphine as found in the serum of patients with sepsis significantly
decrease the secretion of IL-8 from neutrophils.
m Opioid Receptor Expression on Neutrophils
Flow cytometry experiments were performed to determine if
morphine affects m opioid receptor expression. An antibody
(MOR1 N-20) directed against the N-terminal part of the receptor
was used. In order to validate the use of this antibody, we first
performed a Western blot analysis of SH-SY5Y (positive control)
and human neutrophil cell extracts. In both extracts, immunore-
activity was observed as a band at 55 kDa which is consistent with
the expected molecular weight of the m opioid receptor (Fig. 4A). A
control experiment using the secondary antibody alone showed
that no cross reactivity exists (Fig. 4A). PCR was used to determine
whether MOR1 is expressed in human neutrophil under basal
condition and after LPS treatment for 6 h (100 ng/ml). As shown
in Figure 4B, amplification of MOR1 RNA performed on both
naı ¨ve and LPS treated neutrophil total RNA extracts indicates the
presence of a single band at 85 bp, which is also present in total
RNA from SH-SY5Y cells used as a positive control [10]. This
band is absent when RNA is omitted or when the neutrophil RNA
extract is treated with DNAse (Fig. 4B).
Incubation of whole blood with the C-terminal antibody C-20
revealed the same median of fluorescence intensity as incubation
Figure 3. IL-8 secretion from human primary neutrophils. IL-8
secreted from neutrophils expressed as ng/ml of morphine. Morphine
was quantified in culture medium after stimulating 1.10
6 neutrophils
with or without LPS (10 ng/ml, 24 h; n=6), morphine 8 nM (2.5 ng/ml)
and naloxone (10 mM). Basal secretion levels were obtained from
neutrophils incubated without LPS (n=6). *: p,0.05 with a Mann-
Whitney test.
doi:10.1371/journal.pone.0008791.g003
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PLoS ONE | www.plosone.org 8 January 2010 | Volume 5 | Issue 1 | e8791with FITC-anti-IgG as a negative control (Fig. 4C), indicating that
the C-terminal antibody failed to detect m opioid receptor
expression on the neutrophil surface. In contrast, a significantly
higher signal was detected with N-20, which is directed against the
N-terminus of the m opioid receptor (Figure 4C) and confirms the
results of the Western blot.
Flow cytometry experiments using the N-20 antibody were able
to show that, without stimulation, only 5.3763.34% of neutrophils
showed a high level of m opioid receptor expression. However,
after 12 and 24 h stimulation with LPS, this percentage in-
creased significantly (p=0,031) to 13.2868.47% after 12 h and
44.468.06% after 24 h of LPS stimulation (Fig. 4D). There was
Figure 4. Detection of m opioid receptor positive cells by and Western Blot, PCR, and flow cytometry. A. Western blot analysis of 50 mg
of SH-SY5Y (positive control) and human neutrophil extracts with the anti-m opioid receptor (N-20). Control experiment shows the absence of cross
reactivity for the secondary antibody. B. PCR amplification of MOR1 RNA performed on both naı ¨ve and LPS treated neutrophil total RNA extracts
indicates the presence of a single band at 85 bp. Total RNA from SH-SY5Y cells is used as positive control, whereas negative control were done in
absence of RNA and neutrophil RNA extract treated with DNAse. C. Flow cytometry with live gating on neutrophils using either a C-terminal antibody
(C-20) or a N-terminal antibody (N-20). M1, M2 and M3 denote the different histogram gates used for determination of the median of fluorescence
intensity D. Flow cytometry. Whole blood was stimulated with LPS (100 ng/ml) for different time intervals followed by labeling of m opioid receptor
expression on neutrophils with FITC-anti-m opioid receptor (N-20). The percentage of cells showing an increased expression of m opioid receptors is
shown.
doi:10.1371/journal.pone.0008791.g004
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PLoS ONE | www.plosone.org 9 January 2010 | Volume 5 | Issue 1 | e8791no significant change in the median of channel fluorescence
intensity in any of the histogram gates used.
Taken together, these results demonstrate that m opioid receptor
expression on neutrophils is significantly increased after stimula-
tion with LPS.
Characterization of Morphine in the Serum of Patients
with Sepsis
Deproteinized serum extracts (3 patients with sepsis and 3
healthy donors) were purified by solid phase extraction. The
fraction (1/50) resulting from the elution procedure was analyzed
with a Q-TOF MS-MS approach. Comparison with a morphine
standard (Fig. 5A) allowed the unambiguous identification of
morphine (m/z=285.9 Da) and its degradation fragments in
patient extracts (Fig. 5B). Parallel experiments performed on the
serum of healthy donors failed to detect endogenous morphine
(n=3; data not shown).
Serum Morphine Levels in Critically Ill Patients
Using a morphine-specific ELISA kit, morphine concentrations
were quantified in the serum of different patient groups (see
Table 1 for patient categorization) with or without infection. The
mortality was 30%. In septic patients (sepsis, S, n=13; severe
sepsis, SS, n=8; septic shock, SSH, n=10), sources of infection
were respiratory, urinary, or digestive (n=17, 8, and 6,
respectively). Gram negative bacteria were involved in 55% of
the cases and Gram positive bacteria in 45%. Sedation was carried
out without opiates using midazolam and propofol according to
standard protocols. There was no difference between the groups
with regard to mean length of stay on the intensive care unit
(ICU), age and sex. As expected, SOFA scores were higher in
patients with severe sepsis and septic shock (p=0.041).
ELISA analysis revealed that morphine concentrations were
significantly higher in the serum of septic patients compared to
patients with SIRS during the three days of monitoring (Fig. 6).
However, no significant difference was observed between patients
with sepsis, severe sepsis and septic shock. No detectable amount
of morphine was found in 6 healthy controls (data not shown); and
CRP, white cell count and procalcitonin were within normal range
in these individuals (n=6; data not shown). The interquartile
ranges for morphine concentrations in patients with sepsis, severe
sepsis or septic shock were [0,011; 2,194], [0,542; 2,273] and
[0,417; 2,191], respectively. This correlates well with the
morphine concentration (2.25 ng/ml) used for our in vitro
experiments to evaluate the influence of morphine on IL-8
secretion. Thus, it seems likely that the morphine levels found in
septic patients may play a role in regulating neutrophil IL-8
secretion.
In conclusion, our data indicate unambiguously that serum
morphine concentrations increase specifically in patients with life-
threatening infection.
Discussion
In the present study, we have demonstrated (i) that morphine is
present in human neutrophils and is colocalized with lactoferrin,
an antimicrobial peptide released during infection [42] from the
secondary granules of neutrophils, (ii) that LPS and IL-8 trigger
the Ca
2+-dependent secretion of morphine and lactoferrin in vitro,
(iii) that endogenous morphine concentrations are significantly
increased in the serum of patients with septic conditions, (iv) that
the concentration of morphine found in sepsis inhibits IL-8 release
from neutrophils and finally (v) that m opioid receptor surface
expression is increased after stimulation of white cells with LPS.
Our findings provide further evidence for the role of
endogenous morphine [4] as a signaling molecule that can act
through m opioid receptors expressed on immune cells. The
activation of the morphinergic system as demonstrated by an
increase in morphine secretion as well as m opioid receptor
expression by neutrophils, underlines the hypothesis that endog-
enous morphine is part of the innate immune response to stress,
and in particular, infection. In addition, our data suggest a new
link between endogenous morphine expression and host defense
against infection.
During gram-negative sepsis bacterial LPS leads to the
activation of PMN and triggers the synthesis and secretion of
proteases, cytokines (e.g., IL-6 and IL-8), and toxic radicals from
immune cells [43,44]. Among these cytokines, IL-8 acts as a potent
stimulator of PMN and represents a major chemoattractant for
these cells [45,46]. PMN participate in the host defense via the
secretion of particular antimicrobial peptides including lactoferrin,
which is present in secondary granules and is released upon LPS
stimulation [42,47]. Despite their important role in destroying the
pathogen, compounds released by PMN inflict damage to host
cells [48] and contribute to organ dysfunction during systemic
infections. Thus, regulatory mechanisms including the hypotha-
lamic–pituitary–adrenal axis [49], as well as PMN autoregulatory
mechanisms such as apoptosis [50], are necessary to prevent local
tissue destruction [51]. Recently, the m opioid receptor agonist
DAGO in concentrations as low as 10 nM was shown to
significantly decrease the secretion of IL-8 from neutrophils after
LPS stimulation [38]. We now demonstrate that LPS and IL-8
trigger the secretion of morphine from human PMN in vitro. Our
results also indicate that low concentrations of morphine (8 nM
coresponding to 2.25 ng/ml) consistent with the amount of
morphine found in the serum of septic patients, significantly
Figure 5. Characterization of morphine in serum of patients
with sepsis. Top, Q-TOF MS-MS analysis of morphine standard (286.17
Da; 1 pmol). Bottom, Q-TOF MS analysis of 1/50 of the morphine present
in 10 ml of serum from a patient with sepsis.
doi:10.1371/journal.pone.0008791.g005
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that this inhibition can be reversed by naloxone. Therefore, it
is tempting to speculate that morphine present in the serum of
septic patients is secreted from neutrophils and is involved in
the regulation of immunocyte activity. Interestingly, a recent
paper reported that concentrations of morphine as low as
10–100 nM enhanced migration of primary microglial cells
toward adenosine diphosphate. This effect was reversed by
naloxone, as well as CTAP, indicating m opioid receptor
involvement [24]. These data strongly suggest that release of
endogenous morphine may affect immune cells either directly or
via central regulatory mechanisms.
The presence of morphine in human PMN and mononuclear
cells is a matter of dispute: Whilst the presence of morphine was
described by Zhu et al [19], Boettcher and colleagues [20] failed to
demonstrate morphine production within neutrophils. In the
present study, we have unambiguously demonstrated the presence
of morphine in PMN, however, the amount of morphine found
was well below the concentration (0.32+/20.2 pg/million PMN
6 SD vs 12.3365.64 pg/million cells 6 SEM) described before
[19]. A very low amount of morphine was previously found in
erythrocytes by Boettcher and colleagues [20], however, we failed
to show the presence of morphine-like immunoreactivity in these
cells in our experiments.
Atypical cholinergic regulation of morphine secretion from
human white blood cells has been demonstrated before [22]. Our
present study shows that morphine is present in secondary
granules and is secreted from neutrophils in response to LPS
and IL-8 exposure, suggesting that at least part of the circulating
morphine in the blood of septic patients stems from PMN.
Interestingly, this is supported by the observation that LPS
administration in animals dramatically increases the amount of
circulating [29] and cerebral endogenous morphine [28].
However, the low amount of morphine produced and secreted
by neutrophils seems not sufficient to reach the morphine
concentrations observed during sepsis. Thus, during systemic
infection morphine release from the adrenal gland [4,11,15,36], its
delayed glucoronidation in the liver [12] and morphine synthesis
in the nervous system [3,28,52] may potentially contribute to
elevated morphine levels in the systemic circulation.
Morphine preferentially binds to m opioid receptors, a large
family of seven-transmembrane receptors derived from a single
OPRM1 (opioid receptor m) gene. However, endogenous opioid
peptides such as b-endorphine, endomorphines and enkephalins
are also able to bind to m opioid receptors. Serum levels of
endogenous opioid peptides are elevated in response to stress and
also in septic patients [53,54]. Treatment with opiate antagonists
for the cardiovascular effects of septic shock was proposed more
than 20 years ago [55], indicating a key role of opioid peptides in
the stress response. It is likely that part of this response is me-
diated via opioid receptors expressed in different tissues including
endothelia, leukocytes and myocardium. Endogenous opioid
peptides present in the serum of septic patients may compete
with morphine for m opiate receptor binding. However, no effects
of these interactions have been described yet in septic patients.
Thus, further studies are warranted to investigate how endogenous
opioid peptides may influence or possibly regulate morphine-
induced neutrophil inhibition in response to stress and infection.
Stimulation of m opioid receptors (for review: [56,57]), triggers
various effects including direct inhibition of immunocyte function.
Human granulocytes and monocytes express m opioid-like
receptors as demonstrated by specific and saturable binding of
dihydromorphine [58]. m opioid receptors were also found on
human and monkey lymphocytes [59]. A specific m opioid receptor
isoform, the m3 receptor (morphine selective but opioid peptide
insensitive) has also been characterized in human monocytes and
granulocytes as well as in endothelial cells [16,60]. The existence
of numerous splicing variants underpins the complexity of the
morphinergic system [57,60,61]. To date, fourteen human m
opioid receptor isoforms have been identified [56,57,62] with
various affinities for morphine and its derivatives (Ki in the
nanomolar range with low affinity for the recently described
isoform mMOR-1B4 [56,57]), suggesting that different morphine
concentrations are needed for specific receptor isoform activation.
In addition, homo- or hetero-dimerisation of m opioid receptor
subtypes was recently found to occur and to induce switch
signaling [63].
Although it has been shown before that LPS increases m opioid
receptor expression in the rat mesenteries [64], to our knowledge
our results demonstrate for the first time that m opioid receptor
Figure 6. Three-day follow up of morphine concentrations in infected and uninfected patients. Boxplots of endogenous morphine
concentrations measured in the serum of patients with sepsis (n=13), severe sepsis (n=8) and septic shock (n=10), compared to critically ill patients
with SIRS (n=6) over 3 days of monitoring. Patients with sepsis, severe sepsis and septic shock had significantly higher serum concentrations of
morphine than patients with SIRS (Sepsis vs. SIRS, p,0.05; severe sepsis vs SIRS, ,0.01; septic shock vs SIRS, p,0.01).
doi:10.1371/journal.pone.0008791.g006
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with LPS. The expression of m opioid receptors is well documented
for immune and endothelial cells [60,65,66]. Amongst other
opioid receptor subtypes, PMN express the m3 opioid receptor
subtype coupled to constitutive nitric oxide (NO) release
[60,67,68,69]. Due to its immunoinhibitory nature [70,71], it
has been postulated that endogenous morphine down-regulates
immune function to maintain a balance between pro- and anti-
inflammatory processes. In this regard, morphine is known to
dramatically affect innate and adaptive immune responses
[72,73,74,75]. For example, morphine affects lymphocyte prolif-
eration [76,77], natural killer T-cell activities [78,79], antibody
production [80,81], and the number of circulating leukocytes [82].
Inhibition of phagocyte function, such as chemotaxis, phagocyto-
sis, and surface receptor expression after morphine exposure in vitro
is, in part, a consequence of NO synthesis [69] and involves the
modulation of the transcription factors NF-kB and AP-1
[67,68,70,83,84]. In addition, recent data on rat microglial cells
treated with adenosine diphosphate have shown that low
concentrations of morphine induce a biphasic effect, with an
initial phase involving PI3K/Akt pathway activation that leads to
an increase of cell migration [24], followed by a longer-term phase
with increased expression of Iba1 and P2X4 receptor protein,
leading to a greater cell migration.
Furthermore, different m opioid receptor splicing variants are
expressed by PMN, suggesting that these m receptor subtypes may
mediate neutrophil responses during infection. Interestingly, the m
opioid receptor possesses an affinity for morphine with an IC50
around 10nM [85] compatible with the concentration of morphine
observed in the patients with sepsis (8nM or 2.5ng/ml) suggesting
that auto- and/or paracrine regulation involving immune cells and
possibly the endothelium exists.
Several studies have linked endogenous morphine with
inflammatory conditions. Endogenous morphine was found in
the plasma of patients after cardiovascular bypass which induces a
well-described systemic inflammatory response [4,26]. Interesting-
ly, our study shows that morphine levels found in SIRS patients
(mean between 0,39 and 0.57 ng/ml) were comparable to those
described after cardiovascular bypass (mean of 0.75 ng/ml) [26],
wheras morphine was not detected in healthy controls.
Sepsis [86], which is a condition associated with a systemic
inflammatory response caused by bacterial, fungal or viral
infection, is one of the main causes of mortality in intensive care
units [87]. The diagnosis of sepsis is based on clinical symptoms
[40], although several endogenously produced proteins, such as
procalcitonin or C-reactive protein (CRP), have been proposed as
markers of infection and are used in clinical practice [88].
Our study demonstrates a significant increase of serum
morphine levels in patients with severe sepsis or septic shock,
while in critically ill patients suffering from SIRS and controls,
morphine levels were significantly lower. No significant difference
was observed between patients from the three septic groups, but
morphine was undetectable in the serum of healthy donors. Our
results indicate that endogenous morphine might represent a new
biomarker for the diagnosis of sepsis, however, an extended cohort
of patients is needed to validate this hypothesis.
Opioid analgesia is a standard component of sedation in critical
care, with synthetic opiates such as fentanyl and its derivatives
being most frequently used. The clinical significance of sedation-
induced immunosppression is still under debate. So far, no direct
effect of fentanyl in clinically relevant concentrations could be
demonstrated on neutrophil functions and fentanyl does not bind
to opioid receptors expressed on neutrophils [84]. It remains
unclear whether the application of exogenous opiates interferes
with the signaling of endogenous morphine via direct or centrally
mediated mechanisms.
Interestingly, our data reveal that concentrations of morphine
found in the serum of septic patients are in range with the affinity of
m opioid receptors [56]. This correlation suggests a putative
physiological role during sepsis. Based on morphine’s immunoinhi-
bitory activity, it is tempting to propose that during sepsis, increased
morphine levels may down-regulate immune and vascular tissue
responses to prevent organ damage caused by excessive inflamma-
tion. However, recent data suggest that low concentrations of
morphine (10–100 nM), synergistically with other factors increase
immune activity (i.e., migration) [24]. In addition, several studies in
rodents have shown that morphine in clinically relevant doses
exacerbates inflammation and increases sepsis mortality [89,90].
Thus, we cannot exclude that the increase ofendogenousmorphine
may also act in favor of proinflammatory responses in certain cells.
As demonstrated in our study, endogenous morphine concentra-
tions are in the nanomolar range while morphine concentrations
after administration of clinically relevant doses for analgosedation
in intensive care are 10 to 100-fold higher [91]. It is unclear so
far whether the different concentration range of exogenous and
endogenous morphine affects neutrophil function in contrasting
ways. Morphine levels can be related, in part to PMN secretion, but
also to secretion from other organs including adrenal gland and
liver. Therefore, direct monitoring of neutrophil function in relation
to the plasma morphine concentrations is required to eventually
answer this question.
Taken together, our present observations together with
previously published data, support the hypothesis that endogenous
morphine represents a modulator of immune cell activity. Our
data indicate for the first time that endogenous morphine is
secreted from human neutrophils after LPS or IL-8 stimulation. In
patients with generalized infection such as sepsis, severe sepsis, and
septic shock serum levels of endogenous morphine were found to
be dramatically increased, whereas inflammatory states without
infection such as SIRS did not lead to profound endogenous
morphine rises. In addition, our results indicated that low
concentrations of morphine inhibit LPS-induced IL-8 secretion
by neutrophils. Further investigations, including clinical studies,
are required to fully understand the effects of circulating morphine
on immune function in sepsis.
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